Standard of Care (SoC) ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
85	特発性間質性肺炎	2

85. 特発性間質性肺炎

---

臨床試験数 : 627 /  薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05497284 (ClinicalTrials.gov)	November 10, 2022	5/8/2022	To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF	A Participant- and Investigator-blinded, Randomized, Placebo-controlled, Multicenter, Platform Study to Investigate Efficacy, Safety, and Tolerability of Various Single Treatments in Participants With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: LTP001;Drug: Placebo;Drug: Standard of Care (SoC)	Novartis Pharmaceuticals	NULL	Recruiting	40 Years	N/A	All	94	Phase 2	United States;Argentina;Australia
2	NCT03287414 (ClinicalTrials.gov)	December 20, 2017	12/9/2017	Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis	A Subject-, Investigator-, and Sponsor-blinded, Randomized, Placebo-controlled, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: VAY736;Drug: Placebo;Drug: Standard of Care (SoC)	Novartis Pharmaceuticals	NULL	Completed	40 Years	80 Years	All	30	Phase 2	United States;Canada;Germany;Ireland;Italy;United Kingdom;France